Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2025 10:00 ET | Source: Medicovestor Inc

FDA Grants Orphan Drug Designation to Medicovestor’s First-in-Class ADC for Pancreatic Cancer

FDA grants Orphan Drug Designation to Medicovestor’s ADoBind MC001, a novel ADC targeting hard-to-treat pancreatic cancer.
June 09, 2025 10:00 ET | Source: Medicovestor Inc

Medicovestor, Inc. and Sanyou Biopharmaceuticals Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates

Medicovestor and Sanyou team up to develop first-in-class chemoimmunotherapy ADCs, combining AI antibody tech with novel dual-targeting platforms.